Parmax Pharma files Reg 18(6) disclosure of share acquisition by Dhiren Chandulal Shah, Sunil Chinubhai Shah and PACs

What Parmax Pharma announced

Parmax Pharma Ltd (BSE: 540359) submitted a disclosure under Regulation 18(6) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on 17 June 2026. The filing informs the market that Dhiren Chandulal Shah, Sunil Chinubhai Shah and persons acting in concert (PACs) have acquired a substantial block of Parmax Pharma shares. The announcement is limited to the identification of the acquirers; no quantitative details such as the number of shares, percentage of holding, or consideration paid were disclosed.

Parties involved

• Dhiren Chandulal Shah – identified as an individual acquirer.
• Sunil Chinubhai Shah – identified as an individual acquirer.
• PACs – refers to persons acting in concert with the above individuals, as defined under SEBI regulations.

The filing does not elaborate on any relationship among the parties or their intent behind the acquisition.

Regulatory context

Regulation 18(6) requires any person or group acquiring a substantial shareholding (generally 5% or more of the voting share capital) to disclose the acquisition to the stock exchange within a stipulated time frame. The purpose is to ensure transparency and give existing shareholders and the market adequate notice of changes in control.

Key facts at a glance

Why this matters for investors

The disclosure signals that a potentially influential group now holds a material stake in Parmax Pharma. While the exact size of the holding is unknown, the requirement to file under Reg 18(6) implies the stake meets or exceeds the 5% threshold that triggers mandatory reporting. Investors should monitor subsequent filings for details on the share percentage, any changes in board composition, or strategic moves that may arise from the new shareholders' involvement.

A Reg 18(6) filing indicates a substantial acquisition, which can affect voting dynamics and corporate governance.

Conclusion

Parmax Pharma has complied with SEBI’s takeover disclosure rules by reporting that Dhiren Chandulal Shah, Sunil Chinubhai Shah and associated PACs have acquired a substantial shareholding. The filing does not provide the exact size of the stake or the transaction terms. Further disclosures, if any, will be required under SEBI regulations to keep the market fully informed of the evolving shareholding pattern.